Trevi Therapeutics, Inc. (TRVI) vs Vericel Corporation (VCEL)
Trevi Therapeutics, Inc. and Vericel Corporation are both Biotechnology companies. Trevi Therapeutics, Inc. and Vericel Corporation are of similar size ($2.1B and $2.0B). Trevi Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Vericel Corporation trades at 82.6×. Vericel Corporation has the higher net margin (7.91% vs 0.00%) and the higher return on invested capital (5.49% vs −1,412.1%). Across the 14 metrics below, Vericel Corporation leads on 13 and Trevi Therapeutics, Inc. on 1.
Valuation
Profitability
| Metric | TRVI | VCEL | Biotechnology median |
|---|---|---|---|
| Gross margin | 0.00% | 74.56% | 65.16% |
| Operating margin | 0.00% | 5.95% | 0.00% |
| Net margin | 0.00% | 7.91% | 0.00% |
| Free cash flow margin | 0.00% | 20.13% | 0.00% |
| Return on equity | (19.66%) | 7.16% | (57.72%) |
| Return on assets | (18.97%) | 5.16% | (49.22%) |
| Return on invested capital | (1,412.11%) | 5.49% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack